The effect of combination treatment with casirivimab and imdevimab versus standard antiviral therapy on clinical outcomes in hospitalized COVID-19 patients DOI Creative Commons
Sahar K. Hegazy, Ahmed H. Hassan

Deleted Journal, Journal Year: 2024, Volume and Issue: 1(1)

Published: Oct. 14, 2024

Abstract Background The Coronavirus Disease of 2019 (COVID-19) pandemic motivated research efforts to address this catastrophe from the beginning 2020 present. year 2021 is coming an end, and several developments in pharmacotherapy for COVID-19 have occurred. In terms antiviral therapy, monoclonal antibody combinations become one type immunotherapy. Remdesivir favipiravir are two medications typically used treat COVID-19. Paxlovid (nirmatrelvir plus ritonavir) molnupiravir other agents purpose study was compare effects antibodies (casirivimab imdevimab), remdesivir, on swab results hospitalized patients with at discharge. Methods This a phase IV non-randomized controlled trial (< 300 as sample size) no comparison placebo. study, 265 confirmed by polymerase chain reaction (PCR) indications medication were into three groups ratio (1:2:2): REGN3048-3051 (group A), remdesivir B), C). A nonrandomized single-blind design used. study's provided Hospital Mansoura University. Following ethical approval, conducted approximately 6 months. Results Compared favipiravir, casirivimab imdevimab cause less hepatotoxicity, renal impairment, more negative tested antivirals also had significant adverse effects. All considered safe based these findings. Conclusion result better clinical outcomes. toxicity. Trial registration : Clinicaltrials.gov, NCT05502081, 16/08/2022.

Language: Английский

AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants DOI Creative Commons
Nicola Giesen,

Elena Busch,

Enrico Schalk

et al.

European Journal of Cancer, Journal Year: 2022, Volume and Issue: 181, P. 102 - 118

Published: Dec. 10, 2022

Language: Английский

Citations

8
Influence of chronic liver diseases on the course and outcome of COVID-19 DOI Creative Commons
Nikola Mitrović,

Milos Sabanovic,

Ankica Vujović

et al.

PLoS ONE, Journal Year: 2023, Volume and Issue: 18(7), P. e0288350 - e0288350

Published: July 14, 2023

Coronavirus disease of 2019 (COVID-19) is a global health problem. The impact chronic liver diseases on the course and outcome COVID-19 still subject research. aim this study was to show characteristics patients with diseases, establish risk factors for unfavourable outcome.

Language: Английский

Citations

4
Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis DOI
Saeid Mezail Mawazi,

Nousheen Fathima,

Syed Uzair Mahmood

et al.

The American Journal of Emergency Medicine, Journal Year: 2024, Volume and Issue: 85, P. 98 - 107

Published: Sept. 4, 2024

Language: Английский

Citations

1
Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials DOI
Shao‐Huan Lan, Chih‐Cheng Lai, Shen-Peng Chang

et al.

Expert Review of Clinical Pharmacology, Journal Year: 2022, Volume and Issue: 15(6), P. 759 - 766

Published: May 17, 2022

This meta-analysis of randomized controlled trials (RCTs) investigated the clinical efficacy and safety favipiravir for patients with mild-to-critical COVID-19.PubMed, Web Science, Ovid Medline, Embase, Cochrane Central Register Controlled Trials were searched RCTs published before 30 October 2021. Only that compared -based antiviral regimens (study group) other alternative treatments or placebos (control in COVID-19 included.Overall, improvement rate was significantly higher study group than control at assessment conducted after 14 days (OR, 1.83; 95% CI, 1.12-2.98). The virological eradication 28 2.09; 1.15-3.78). No significant difference observed rates invasive mechanical ventilation requirement ICU admission, mortality, risk an adverse event between groups.Except within days, favipiravir-based treatment did not provide additional benefit COVID-19. Therefore, more evidence is necessary.

Language: Английский

Citations

7
The effect of combination treatment with casirivimab and imdevimab versus standard antiviral therapy on clinical outcomes in hospitalized COVID-19 patients DOI Creative Commons
Sahar K. Hegazy, Ahmed H. Hassan

Deleted Journal, Journal Year: 2024, Volume and Issue: 1(1)

Published: Oct. 14, 2024

Abstract Background The Coronavirus Disease of 2019 (COVID-19) pandemic motivated research efforts to address this catastrophe from the beginning 2020 present. year 2021 is coming an end, and several developments in pharmacotherapy for COVID-19 have occurred. In terms antiviral therapy, monoclonal antibody combinations become one type immunotherapy. Remdesivir favipiravir are two medications typically used treat COVID-19. Paxlovid (nirmatrelvir plus ritonavir) molnupiravir other agents purpose study was compare effects antibodies (casirivimab imdevimab), remdesivir, on swab results hospitalized patients with at discharge. Methods This a phase IV non-randomized controlled trial (< 300 as sample size) no comparison placebo. study, 265 confirmed by polymerase chain reaction (PCR) indications medication were into three groups ratio (1:2:2): REGN3048-3051 (group A), remdesivir B), C). A nonrandomized single-blind design used. study's provided Hospital Mansoura University. Following ethical approval, conducted approximately 6 months. Results Compared favipiravir, casirivimab imdevimab cause less hepatotoxicity, renal impairment, more negative tested antivirals also had significant adverse effects. All considered safe based these findings. Conclusion result better clinical outcomes. toxicity. Trial registration : Clinicaltrials.gov, NCT05502081, 16/08/2022.

Language: Английский

Citations

1